Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Deferred Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Current Deferred Revenue for 16 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 79.14% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 79.14% decrease, with the full-year FY2024 number at $8.0 million, down 56.52% from a year prior.
  • Current Deferred Revenue was $2.9 million for Q3 2025 at Dexcom, down from $6.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $18.4 million in Q4 2023 to a low of $1.8 million in Q2 2021.
  • A 5-year average of $7.5 million and a median of $7.8 million in 2025 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 380.95% in 2022, then plummeted 79.14% in 2025.
  • Dexcom's Current Deferred Revenue stood at $2.1 million in 2021, then skyrocketed by 380.95% to $10.1 million in 2022, then skyrocketed by 82.18% to $18.4 million in 2023, then crashed by 56.52% to $8.0 million in 2024, then tumbled by 63.75% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Current Deferred Revenue are $2.9 million (Q3 2025), $6.1 million (Q2 2025), and $7.8 million (Q1 2025).